These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38594266)

  • 1. KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.
    Ni C; Wang X; Liu S; Zhang J; Luo Z; Xu B
    Sci Rep; 2024 Apr; 14(1):8284. PubMed ID: 38594266
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Huang K; Ding S; Chen K; Guo C; Wu M; Zhang R; Wang L; Fu Y; Xiao J; Liu X
    Am J Cancer Res; 2023; 13(11):5549-5558. PubMed ID: 38058823
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.
    Liu R; Niu Y; Liu C; Zhang X; Zhang J; Shi M; Zou W; Gu B; Zhu H; Wang D; Yuan H; Li W; Zhao D; Zheng Q; Liu R; Chen W; Ma T; Zhang Y
    Cancer Sci; 2023 Apr; 114(4):1229-1239. PubMed ID: 36601880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors.
    Lin Y; Luo S; Luo M; Lu X; Li Q; Xie M; Huang Y; Liao X; Zhang Y; Li Y; Liang R
    Mol Carcinog; 2023 Sep; 62(9):1271-1283. PubMed ID: 37232365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of SPEN Mutations as Predictive Biomarkers for Immunotherapy Response in Colorectal Cancer: Insights from a Retrospective Cohort Analysis.
    Dong Y; Ye S; Li H; Li J; Liu R; Zhu Y
    J Pers Med; 2024 Jan; 14(2):. PubMed ID: 38392565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
    Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
    Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients.
    Wang Y; Chen H; Jiao X; Wu L; Yang Y; Zhang J; Wu L; Liu C; Zhuo N; Li S; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Lu Z; Zhang H; Shen L
    Cancer Immunol Immunother; 2022 Jan; 71(1):111-120. PubMed ID: 34028566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated Profiling Identifies
    Shi J; Bao M; Wang W; Wu X; Li Y; Zhao C; Liu W
    Front Immunol; 2021; 12():722807. PubMed ID: 34646265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].
    Qin CP; Song YX; Ding MT; Wang F; Lin JX; Yang WB; DU YQ; Li Q; Liu SJ; Xu T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):663-668. PubMed ID: 35950389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression.
    Larsson C; Cordeddu L; Siggens L; Pandzic T; Kundu S; He L; Ali MA; Pristovšek N; Hartman K; Ekwall K; Sjöblom T
    Clin Epigenetics; 2020 May; 12(1):74. PubMed ID: 32471474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.
    Wang Z; Ge Y; Li H; Fei G; Wang S; Wei P
    Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36305643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in lysine methyltransferase 2C and PEG3 are associated with tumor mutation burden, prognosis, and antitumor immunity in pancreatic adenocarcinoma patients.
    Huang Y; Liu J; Zhu X
    Digit Health; 2022; 8():20552076221133699. PubMed ID: 36312851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of an immune prognostic signature in colorectal cancer.
    Li M; Wang H; Li W; Peng Y; Xu F; Shang J; Dong S; Bu L; Wang H; Wei W; Hu Q; Liu L; Zhao Q
    Int Immunopharmacol; 2020 Nov; 88():106868. PubMed ID: 32771948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APC mutation correlated with poor response of immunotherapy in colon cancer.
    Li B; Zhang G; Xu X
    BMC Gastroenterol; 2023 Mar; 23(1):95. PubMed ID: 36977982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan‑cancer analysis on the role of KMT2C expression in tumor progression and immunotherapy.
    Cao W; Xie Y; Cai L; Wang M; Chen Z; Wang Z; Xv J; Wang Y; Li R; Liu X; Wang W
    Oncol Lett; 2024 Sep; 28(3):444. PubMed ID: 39091583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.